Welcome to article directory San Antonio Homes. Here You can find interesting and useful information on most popular themes.

There are 1979 published articles and 1 registered authors in our article directory.

Recent Articles

Actos Warning Breaking News

By admin | Published January 26, 2012

Actos Warning : One study of municipal distribution of BC in Spain detected 34,281 BC deaths registered between 1989 and 1998. They could observe that determinate zones exhibited a higher risk than others, these being provinces of Cadiz, Seville, Huelva, Barcelona, and Almeria. The municipal mortality patterns suggested that the industrial and mining activity in the Provinces of Seville and Huelva could be associated with higher BC mortality in these provinces. The mortality pattern assessed in two different areas of the Province of Barcelona, which is only observable in women, might be related to the textile industry traditionally situated in these areas (Lopez-Abente et al. 2006).The trend to decrease BC due to occupational exposure was reported in a pooled analysis of 11 case-control studies on BC conducted in European countries between 1976 and 1996. This analysis included 3346 male cases and 6840 male controls. Thirty-one occupations showed increase risk for BC and these occupations were grouped as metal workers, textile workers, painters, miners, and transport opera­tors. Higher odd ratios were observed on those people with duration of employment more than 25 years. However, the author concluded that the ratio of BCs caused by occupational exposure was lower than those identified one year ago and that the exposure to occupational carcinogens had been reduced in the European Union.

 

More information on Actos Warning

This would likely be due to the improvement in working conditions and the reduction of exposure, particularly, to aromatic amines in work. Currently, employ­ments that relate more to BC risk are those in metal sector, machinists, transport operators, and miners (Kogevinas et al. 2003).In addition to the analysis on men, a pooled analysis of 11 case-control studies in BC conducted in Western Europe showed that the rates of BC due to occupa­tional exposure had been reduced in women, with only a 8% of BC in women attributable to occupational carcinogens (Mannetje et al. 1999). Although in devel­oped countries strict regulatory controls may have contributed to a decreased bur­den of exposure to bladder carcinogens in the workplace, the situation is less apparent in developing countries.

Information from other sources on Actos Warning

As in BC, in general, occupational case is more frequent in men than in women, although, an increased risk among women has been documented in several studies, including those employed in the rubber industry and, more recently, in healthcare settings. In a case-control study conducted in Iowa, female teachers, domestic ser­vice employees, and workers in laundering and dry-cleaning business had elevated risk of BC. Other gender and racial differences had been documented in occupa­tional BC. In this way, in a recent mortality study in the United States, the mortality ratios for AA men and women and Latino males in various occupations were found to be increased compared with workers of the same gender and ethnic-racial group (Delclos and Lerner 2008).

 

Our use of the term or terms Actos Warning is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Warning visit our site often.

http://www.seedol.com

Posted in Alex Begum | Tagged | Leave a comment

Actos and Bladder Cancer News Flash

By admin | Published January 26, 2012

Actos and Bladder Cancer : Bladder cancer treatment can include surgery, chemotherapy, radiation therapy, and immunotherapy. Although some of these treatments are used alone, often a combination of several treatments (i.e., both chemotherapy and surgery) is used for the most success. Selection of the most appropriate treatment is based on clinical staging, including pathological and ra­diographic information, and individual preference in close consultation with your physician. When choosing a blad­der cancer treatment, it is important that you consider not only the potential for cancer cure but also the side effects and quality of life impact of various treatments.

More information on Actos and Bladder Cancer

SURGICAL TREATMENT

Surgery plays an important role in both the staging and subsequent treatment of bladder cancer. Transurethral resection of a bladder tumor (TURBT) is the initial treat­ment step in the vast majority of patients with bladder cancer. TURBT provides valuable staging information, and pathological results from these procedures are used to make further decisions regarding what, if any, addi­tional therapy is needed. The gold standard treatment for muscle-invasive bladder cancer is radical cystectomy (removal of the bladder). Advances in surgical technique and anesthesia have reduced the complications associated with this procedure in the last two decades. The develop­ment of continent urinary diversion, which allows one to empty the bladder through the urethra, is an option for certain patients. Minimally invasive procedures such as laparoscopic or robotic-assisted radical cystectomy may also be treatment options. In addition, bladder-sparing procedures (either with partial removal of the bladder or aggressive TURBT frequently in combination with che­motherapy and/or radiation therapy) have allowed some patients to treat their cancer while leaving their blad­ders intact. Advances in surgical techniques continue to this day with the development of minimally invasive approaches to cystectomy. Both robotic-assisted and lapa­roscopic radical cystectomy have been performed safely in highly specialized centers and have the potential for decreased morbidity and a shorter period of recovery, but longer term follow-up is needed to determine if these pro­cedures are equivalent to open surgical techniques.

 

Information from other sources on Actos and Bladder Cancer

TURBT is often the first procedure you will have once diagnosed with a bladder tumor. This surgery is typically performed under general or spinal anesthesia as an out­patient procedure and without any incision, endoscopically through the urethra, which means a cystoscope is placed through the urethra and into the bladder. Through this scope your urologist can see the inside of your bladder and has the ability to resect, or remove, tumors in the bladder under direct vision using electrocautery. The electrocautery is also used to control bleeding after the resection is com­pleted. TURBT is extremely important for the staging of bladder tumors but can also be therapeutic for lower stage bladder cancers. Once the tumor has been removed, it can be analyzed under the microscope by a pathologist. The pathological findings dictate further treatment decisions. If the tumor is low grade and noninvasive, you will likely not need any further therapy at this point except for close follow-up.

 

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

Actos and Bladder Cancer

Posted in Alex Begum | Tagged | Leave a comment

Actos Bladder Cancer Release

By admin | Published January 26, 2012

Actos Bladder Cancer : Despite prompt and appropriate medical treatment if you have mus­cle-invasive TCC, there is about a 50 percent chance that your cancer will metastasize (spread), either to another organ in the body or with­in the bladder area itself. The most common sites of “distant metastasis” (not in the imme­diate area of the bladder) are the para-aortic lymph nodes and the liver, lungs, and bone. Occasionally, bladder cancer can send deposits through the bloodstream to the brain, but usually this happens only after prolonged and repeated treatment. Most recurrences, both dis­tant and local, occur within the first two years after treatment.

One point worth emphasizing is that cancer cells in a distant metastasis still have the characteristics of the bladder cancer (i.e., they behave in the pattern of those bladder-cancer cells and don’t really constitute ” bone cancer”or “liver cancer”as such).Thus the drugs that may work against bladder-cancer cells also have a chance of working against these metastases located at other sites in the body.

As you might expect, the metastasis of your cancer is a dangerous situation that reduces your chance of a permanent cure. That doesn’t mean that cure is impossible or that you no longer have options. Some established chemotherapy approaches can sometimes achieve cure if the metastases are not too extensive. In addition, new and promising therapies, including novel chemotherapy drugs, are under­going clinical trials as this book goes to print, and many of those may well be available to you.

More information on Actos Bladder Cancer

When metastasis occurs, the direction of your treatment shifts somewhat from a totally focused attempt to achieve cure. In this situ­ation/ while we attempt to cure the metastatic cancer if possible/ we also tty to palliate (reduce) the symptoms and we place a greater emphasis on comfort and pain control This type of treatment is called palliative care. At this point, not only you but your family and loved ones should be involved with your medical team in understanding the progression of your disease and making decisions about your care.

This is a very important point and it can be confusing. On the one hand, your medical team is still trying very actively to cure the cancer, if possible, and to prolong your life and improve its quality to the maximum extent. However, as the chance of cure is somewhat small­er, you and your medical team must also give thought to the benefits and drawbacks of treatment, to quality-of-Hfe issues, and to making the decisions that make the most sense. You and they will want to weigh the chance that treatment might be successful against the possible side effects, the time spent in treatment, and the possible limitations on your quality of life.Your doctor may discover the metastasis during a routine check­up, although sometimes a patient will experience symptoms.

Information from other sources on Actos Bladder Cancer

might be bone pain, abdominal discomfort severe headache, or tin­gling in the legs. (The latter may occur if a metastasis is pressing on nerves in the spine.) Perhaps weight has been lost without changing exercise or diet habits. One might develop a cough or abdominal pain, or experience hematuria (blood in the urine) or other symp­toms of bladder irritation. Any of these symptoms should send you to the phone to make an appointment with your doctors to figure out whether something sin­ister is beginning to occur. As you read this you might be thinking that if the cancer is so advanced – if it has spread to the lungs or bones what’s the point of treating symptoms like tingling in your legs or vague abdominal pain?

The point is that even though the cancer has advanced and metas­tasized, you are likely to live for an extensive period of time – months or years – and it makes good sense to make sure that you are able to live that time comfortably and as fully as possible. If you allow symp­toms to go untreated, your ability to participate in everyday life with your family and friends may be greatly diminished, and the time you have left with them may be cut short. On the other hand, occasionally a specialist may decide to watch and wait. For example, when a change is seen on an x-ray but there are no symptoms. Or when a patient is unwell from other medical problems or is just keen to avoid treatment at that time. In such situ­ations, sometimes the decision will be made to observe closely and start treatment when symptoms occur.

What kind of treatment can one expect if the cancer metastasizes? Surgery to remove the bladder is occasionally a possibility if the only site of recurrence is the bladder and surrounding tissues. It usually doesn’t make sense to operate if the cancer has spread to distant sites. Sometimes radiotherapy will be used to reduce the symptoms of recurrence in the bladder if the recurrence is too extensive to permit surgery or if distant metastases have also occurred.

Our use of the term or terms Actos Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Bladder Cancer visit our site often.

Actos Bladder Cancer

Posted in Alex Begum | Tagged | Leave a comment

Yaz Lawsuit News

By admin | Published January 25, 2012

Yaz Lawsuit News 1/23/2012: Until recently, it had appeared self-evident that (nonembolic) arterial thrombosis was the culmination of slow enlargement of the mature atherosclerotic lesion with progressive encroachment into the arterial lumen. This pathobiological construct supported the view that the risk of acute thrombosis was dominated by the sever­ity of arterial stenosis. However, over the past decade, angiographic and patholog­ical data obtained in the coronary arterial bed have challenged this construct. Angiography performed prior to or at the time of acute myocardial infarction has demonstrated that the infarct-related coronary atherosclerotic lesion is frequently not ‘‘critical’’ by standard angiographic criteria. Similarly, pathological examination of culprit lesions has demonstrated that the majority of acute coro­nary events occur with the formation of thrombus at the site of plaques obstruct­ing <50% of the arterial lumen. Taken together with evidence for the impor­tance of plaque disruption in the development of superimposed thrombus (56,65­69), such data have shifted focus from the degree of luminal stenosis to the mor­phological and histological characteristics of the atheromatous plaque that deter­mine its propensity to rupture.

Lending further support to the contribution of inflammatory mechanisms to plaque destabilization, onset of acute thrombosis with or without myocardial necrosis is marked by the production of a number of inflammatory cytokines. In addition, a series of studies have suggested a link between the elabo­ration of inflammatory cytokines and impairment of the ability of smooth muscle cells to maintain the integrity of the fibrous cap (52). Interferon-gamma (IFN-y), a cytokine produced by T-lymphocytes within the atheroma core, decreases the production of collagen by vascular smooth muscle cells (80-82). Smooth muscle cells at the site of plaque rupture or erosion have been found to express high levels of the transplant antigen HLA-DRa, a protein induced only by IFN-y among a wide spectrum of cytokines evaluated

More information on Yaz Lawsuit:

Vascular inflammation may also influence arterial vasomotor function through several possible mechanisms. Increased concentrations of thromboxane A2 and its metabolites produced in acute coronary syndromes (99,100) mediate further platelet aggregation as well as arterial vasoconstriction (101). Leukocytes also produce en- dothelin-1, a potent modulator of vasoconstriction. In addition, certain inflammatory cytokines may increase vascular smooth muscle cell reactivity, as demonstrated in an animal model with IL-1 (102). Finally, inflammatory infiltrates have been documented in the arterial adventitia with vascular nerve involvement and thus have been hypothesized to directly stimulate coronary vasospasm.

In spite of continued advancements in the management of acute ischemic heart disease, morbidity and mortality due to atherosclerotic vascular disease continue to rise globally. Thus, the impetus for improving our strategies for the prevention and management of atherosclerosis has remained strong. In this re­gard, laboratory and experimental research describing key processes in the initia­tion, progression, and destabilization of the atheroma have pointed to novel direc­tions for cardiovascular evaluation and management. In particular, recognition of the role of inflammation in atherothrombosis has directed attention to inflam­matory mediators and indicators as potential targets for risk assessment and for treatment.

Information from other sources on Yaz Lawsuit:

Epidemiological data have established a well-characterized set of vascular risk factors, including advanced age, tobacco use, obesity, diabetes, hypertension, and dyslipidemia. However, up to one-third of first coronary events occur among individuals without these traditional risk factors. Researchers have thus sought to identify inflammatory indicators that might add to these clinical factors for predicting myocardial infarction and stroke. Candidate markers have included several of the cytokines (77,108,109) that promote the recruitment of monocytes in response to endothelial cell dysfunction; intercellular adhesion mol­ecules that mediate the migration of activated monocytes into the subendothelial space; enzymes that might compromise the integrity of the protective fibrous cap, as well as the acute-phase proteins that are produced and released into the systemic circulation in response to inflammatory cytokines.

With systemic levels that are dependent on the rate of de novo hepatic production, CRP levels remain stable over long periods of time in the absence of new stimuli. However, in response to acute tissue injury, infection, or other inflammatory stimuli, CRP levels rise several hundred-fold. As such, CRP and its acute-phase counterpart, serum amyloid A, have been useful in fol­lowing disease activity in chronic inflammatory conditions such as systemic lu­pus, inflammatory bowel disease, and rheumatoid arthritis. Traditional semiquantitative latex agglutination or standard turbidometric methods have been adequate to evaluate such marked elevation of CRP in these disease processes. In contrast, the development of high-sensitivity assays for CRP (hs-CRP) has now enabled detection of CRP within the normal range for healthy individuals. Further, the introduction of high through-put methods with high ana­lytical sensitivity and reproducibility has provided a simple clinical tool to care­fully evaluate the extent of underlying systemic inflammation.

Yaz Lawsuit: More information from other sources related to your search

Antiphospholipid antibodies (APLA) are a heterogeneous group of autoantibod­ies associated with both arterial and venous thrombosis, recurrent pregnancy loss, and thrombocytopenia. They can occur either in association with other auto­immune conditions, most frequently systemic lupus erythematosus (SLE), or in isolation, a condition known as the primary antiphospholipid antibody syndrome. In the research laboratory, many antiphospholipid antibodies (with varying epi­tope specificity) can be identified. However, in clinical practice, the antiphospho­lipid antibodies are divided into two large groups, the lupus anticoagulants and the anticardiolipin antibodies.

Lupus anticoagulants or nonspecific inhibitors interfere with the assembly of procoagulant complexes. In vitro, these antibodies are associated with the pro­longation of phospholipid-dependent blood-clotting times. Characteristically, clotting times return to normal with the addition of exogenous phospholipid. Lu­pus anticoagulants may demonstrate specificity for blood-clotting proteins, in particular prothrombin. However, the mechanism by which they promote throm­bosis is unknown. Lupus anticoagulants are likely associated with a high risk of first and recurrent thrombosis as well as recurrent pregnancy loss.

Yaz Lawsuit: Additional News and Information about Yaz Lawsuit:

APLA are found in about 20% of patients presenting with venous thromboembo­lism (1,2), in about 10% of patients presenting with first ischemic stroke (3), and in approximately 5 to 10% of young people presenting with first myocardial infarction (4). Their prevalence in the unselected population is unknown; reported rates vary widely with the test system used and the population being studied. About 30% of individuals with systemic lupus erythematosus have an APLA (5). Low-titer anticardiolipin antibodies are frequently detected in otherwise well individuals; repeat testing reveals a high rate of spontaneous resolution.

All patients with unexplained venous thrombosis, in particular those with thrombosis in unusual sites (such as the cerebral veins or mesenteric veins), should be screened for an antiphospholipid antibody. Both a lupus and an anticar- diolipin antibody should be sought. Testing should be carried out in accordance with the recommendations of the International Society of Thrombosis and He- mostasis, with appropriate confirmatory assays for suspected lupus anticoagu­lants.

Many questions remain unanswered in patients with antiphospholipid antibodies. First, many patients, particularly those with systemic lupus erythematosus, are screened for the presence of an antiphospholipid antibody despite their never having had an episode of thrombosis. When detected, the clinical importance of the antibody is unknown. As a result, some such patients (who are suspected to have a high risk of first thrombosis) are treated with warfarin with varying INR target ranges, while others are treated with aspirin or other antiplatelet agents, and many receive no antithrombotic prophylaxis. To address the need for routine antithrombotic prophylaxis in this problematic patient population, a large, ran­domized clinical trial is currently being carried out. Within this study, adults and children, with both an antiphospholipid antibody and systemic lupus erythemato­sus, are allocated to long-term warfarin with a target INR of 2.0, or no therapy. The primary outcome measure of the study is the rate of objectively confirmed arterial and venous thrombosis.

Our use of the term or terms Yaz Lawsuit: is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Yaz Lawsuit :visit our site often.

http://www.seedol.com

Posted in Alex Begum | Tagged | Leave a comment

Vaginal Lawsuit Petition

By admin | Published January 25, 2012

Vaginal Lawsuit : Oestrogen receptors have been demonstrated in the squamous epithelium of both the proximal and distal urethra.24 Oestrogen has been shown to improve the maturation index of urethral squamous epitheLium.25It has been suggested that oestrogen increases urethral closure pressure and improves pressure transmission to the proximal urethra, both of which promote continence. Epidemiological studies have implicated oestrogen deficiency in the aetiology of lower urinary tract symptoms. Seventy percent of women relate the onset of urinary incontinence to their final menstrual period.2 Lower urinary tract symptoms have been shown to be common in postmenopausal women attending a menopause clinic, with 20% complaining of severe urgency and almost 50% complaining of stress incontinence.

There is, however, conflicting evidence regarding the role of oestrogen withdrawal at the time of the menopause. Some studies have shown a peak incidence in perimenopausal women36‘37 whilst other evidence suggests that many women develop incontinence at least 10 years prior to the cessation of menstruation, with significantly more premenopausal women than postmenopausal women being affected.

For more information on Vaginal Lawsuit follow us on our RSS Feeds.

Urinary tract infection is also a common cause of urinary symptoms in women of all ages. This is a particular problem in the elderly with a reported incidence of 20% in the community and over 50% in institutionalized patients.39‘40 Pathophysiological changes, such as impairment of bladder emptying, poor perineal hygiene and both faecal and urinary incontinence, may partly account for the high prevalence observed. In addition, as previously described, changes in the vaginal flora due to oestrogen depletion lead to colonization with Gramnegative bacilli, which, as well as causing local irritative symptoms, also act as uropathogens. These microbiological changes may be reversed with oestrogen replacement following the menopause, offering a rationale for treatment and prophylaxis.

Information from other sources on Vaginal Lawsuit

Oestrogen preparations have been used for many years in the treatment of urinary incontinence,41‘42 although their precise role remains controversial. Many of the studies performed have been uncontrolled observational series examining the use of a wide range of different preparations, doses and routes of administration. The inconsistent use of progestogens to provide endometrial protection is a further confounding factor making interpretation of the results difficult.

Our use of the term or terms Vaginal Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Vaginal Lawsuit visit our site often.

.

Posted in Alex Begum | Tagged | Leave a comment

Trans Vaginal Mesh Lawsuit Data

By admin | Published January 25, 2012

Trans Vaginal Mesh Lawsuit : Fistulae are rare in England and are usually secondary to gynaecological surgery, maLignancy or radiotherapy. A fistula is an abnormal connection between two epithelial surfaces. Surgical procedures associated with vesicovaginal fistula. Obstetric fistulae are much commoner in the developing world and are a frequent reason why women are cast out of their homes and communities and abandoned. Urethrovaginal and ureterovaginal fistulae are much less common than vesicovaginal fistulae. In the developed world they are unusual causes of urinary incontinence (UI). Once again, the most common cause of these fistuale in the developing world is obstetric trauma due to ischaemic necrosis; in developed countries the most common cause is surgery. Anterior repair, vaginal hysterectomy and urethral diverticulectomy have all been associated with an increased risk of urethral fistula formation.

USI, as opposed to the patient symptom ‘stress urinary incontinence’ (SUI), is only diagnosed after performing urodynamics and is the involuntary leakage of urine per urethram during periods of raised intraabdominal pressure, in the absence of a detrusor contraction. Normal urethral function maintains a positive urethral closure pressure in the presence of raised intraabdominal pressure, although DO may overcome it. An incompetent urethra allows leakage of urine, even in the absence of a detrusor contraction. Damage to the pubo- urethral ligaments and the levator ani muscles (secondary to pregnancy, childbirth, obesity, radical pelvic surgery, abdominopelvic mass or chronic cough, and possibly exacerbated by inherited weak collagen) may allow bladder- neck hypermobility and descent of the bladder neck and proximal urethra, so that they are no Longer within the intraabdominal pressure zone.

For more information on Trans Vaginal Mesh Lawsuit follow us on our RSS Feeds.

demonstrated denervation of the intrinsic and extrinsic sphincter mechanisms.5,6This is known as ‘intrinsic sphincter deficiency’, where the hermetic closure properties of the proximal urethra are lost and USI may be the result. From September 2004 the first drug treatment for SUI, duloxetine, will be available. It is essential to be sure of the diagnosis by excluding DO (see Chapter 6) – a minority of patients opting for a surgical treatment develop irritative symptoms of urgency and frequency or voiding difficulty postoperativeLy, and pre­existing symptoms are likely to be exacerbated.

DO is a urodynamic observation characterized by involuntary detrusor contractions that may be spontaneous or provoked. The contractions occur during the filling phase. Phasic DO is defined by a characteristic waveform that mimics the normal voiding cycle, but which does not inevitably lead to UI. Terminal DO is defined as a single involuntary detrusor contraction at cystometric capacity, which cannot be suppressed, and leads to incontinence – usually complete – and catastrophic bladder emptying.7 Provoked DO is the association of a detrusor contraction with either a physical provocation to the bladder, such as coughing and standing, or a psychological provocation such as hearing running water.

Information from other sources on Trans Vaginal Mesh Lawsuit

Symptomatically, these patients are similar to, and often indistinguishable from, patients with DO. Sometimes, however, low compliance may be associated with a fast bladder-filling rate. Low compliance is seen less often at Patients with DO are often indistinguishable from patients with low compliance; however, low compliance may be associated with a fast bladder-filling rate and is seen less often at physiological filling rates. The incidence of DO increases with age, and urge incontinence is the commonest symptom of incontinence in people aged over 60 years8 and the elderly.9 Urodynamic assessment is required to make an accurate diagnosis, as women usually present with multiple symptoms, most commonly a syndrome of frequency, urgency and nocturia. The pathophysiology of DO is poorly understood and an underlying cause is rarely found, leading to the term idiopathic DO. Detrusor overactivity and USI can coexist as mixed incontinence and DO can arise de novo after incontinence surgery.

Our use of the term or terms Trans Vaginal Mesh Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Trans Vaginal Mesh Lawsuit visit our site often.

Trans Vaginal Mesh Lawsuit

Posted in Alex Begum | Tagged | Leave a comment

Mesothelioma Cancer Information

By admin | Published January 25, 2012

Mesothelioma Cancer : After performing the physical exam and taking a his­tory that concentrates on whether you have developed shortness of breath or pain, the doctor will order a chest x-ray. Based on what is found, the doctor will determine what other tests you will need. The doctor may also order blood work. When a tumor or fluid is found, the doctor will need to perform a procedure that mil obtain cells for the physicians to study to determine whether this is a cancer or not. This can be done by performing a biopsy of the mass or by tapping fluid (inserting a needle and drawing out fluid) from the chest or belly cavity and then analyzing the cells that come with the fluid. The analysis of cells from fluid is called cytology. Although an x-ray or scan may provide useful information about the size, shape, and location of a tumor or fluid and may alert your doctor to the possibility of a cancer, an actual diagnosis of mesothelioma cannot be made without a biopsy, or undeniable evidence of cells in the fluid that have the characteristics of a mesothelioma. Mesothelioma Cancer

For more information on Mesothelioma Cancer follow us on our RSS Feeds.

There are no specific blood tests that can tell your doctor you have mesothelioma. Certain blood cell values may be abnormal when a patient has mesothelioma, but these are nonspecific (that is, they do not definitively tell the doctor that it is mesothelioma or another type of cancer or a benign condition). The white blood cell count (cells that fight infection) may be elevated and/or the platelet count (cells that help the clotting system) maybe elevated above normal values.

The liquid part of blood (serum) is partially comprised of dissolved proteins. Currendy, there are no specific proteins in the serum that can tell your doctor you have asbestosis or mesothelioma. Proteins that are spe­cific to a certain disease are called biomarkers. There is great interest in the discovery of these biomarkers, which may represent unique proteins from the tumor that appear early in the disease and increase as the dis­ease progresses. Ask your physician whether any of these markers are under study or whether any have been approved by the FDA for the study of mesothe­lioma. These markers include soluble mesothelin related protein (SMRP) and osteopontin. Mesothelioma Cancer

Information from other sources on Mesothelioma Cancer

The results of the chest x-ray will usually prompt the doctor to order a CAT or CT scan (computerized axial tomography scan) of the chest and abdomen. These scans provide a three-dimensional view of the area of the body that the physician is interested in. CT scans have a better ability to show how much solid mass is present and how much fluid contributes to the picture. They also give a much better anatomic picture so your doctor can see how any masses relate to the lung, heart, diaphragm (the muscle that helps you breathe), and blood vessels in the chest or abdomen. CT scans do not tell the doctor what type of tumor it is or whether the disease has invaded other structures, but they do give a very good idea of whether your disease can be classified as early with minimal disease (Stage I), later with moderate amount of disease (Stage II), or advanced with a large amount of disease (Stages III and IV). (We will discuss the concept of staging in more detail later on.) In mesothelioma, a CT scan is not very good for showing whether your lymph nodes (the round structures in certain positions in the chest and abdomen that drain the lung and intestines and act as filters and sites for immune responses) are involved. The reason it does not show this well is that the pleura can be thickened in areas where the lymph nodes are, and this lumpy, bumpy thickening can be confused with lymph nodes or can hide lymph nodes.

Our use of the term or terms Mesothelioma Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Mesothelioma Cancer visit our site often.

Mesothelioma Cancer

Posted in Alex Begum | Tagged | Leave a comment

Actos Lawsuit Legal Scoop

By admin | Published January 25, 2012

Actos Lawsuit: To understand cancer, we must first understand nor­mal functioning of the body. The body is made up of billions of cells. Each organ of the body is made up of several different types of specialized cells. For example, the liver has cells that filter toxins from the blood, and the brain has nerve cells (called neurons) that are able to conduct electrical signals. Perhaps the most familiar cells are skin cells. Every flake of dry skin is made of millions of cells that are constantly dying and being replaced with new cells. The growth of new cells is care­fully balanced to occur at the same rate as the death of old cells. Your body has many mechanisms in place to regulate the timing of the birth and death of cells. Unfortunately, if one of these mechanisms malfunc­tions, the careful balance can be disrupted. Environ­mental toxins such as cigarette smoke, chemicals, and radiation can damage DNA and can disrupt these control mechanisms. A tumor may develop when new cells are created faster than old cells die. Tumors can be either benign or malignant. A benign tumor is an overgrowth of cells that is unchecked by the body’s normal mechanisms; thus, it will keep getting bigger. It is called benign because it does not cause you illness. Some benign tumors can get to be so large that they do cause problems, especially if they are in a confined space, such as your skull. A malignant tumor is also an overgrowth of cells.

You can live without a bladder. However, you still need something that can perform the two basic func­tions of the bladder: storing and emptying of urine. Physicians have come up with many ways over the years to accomplish these tasks, many of which are still used today. The simplest alternative is to place drainage tubes into the kidneys that come out through the skin and connect to bags on the abdomen. These tubes are known as nephrostomy tubes. Nephrostomy tubes are typically inserted into a person in the X-ray department by an interventional radiologist who uses some light sedation. For the patient, the bag provides an easy way to store urine and can be drained several times a day when convenient by opening a small valve on the bag.

For more information on Actos Lawsuit follow us on our RSS Feeds.

To provide a good long-term solution, surgeons most commonly use a portion of the small bowel to act as the new bladder. The identified piece of small bowel is removed from the main portion and is fashioned for its new use (see Question 79 for details). The urine that collects within this piece of bowel will ultimately be drained in one of three ways. First, the bowel can simply be left open at the skin for the urine to drain passively out into a bag that is attached to the abdomen. This type of drainage is known as a conduit, and the opening onto the skin is called a urostomy. Urine collects in the bag, which is then drained into a toilet several times each day. Second, the bowel can be sewn into a rough sphere con­nected to the skin by only a small, long channel. This channel prevents urine from leaking out but easily accommodates a small catheter. This is called a conti­nent urinary diversion. With this type of diversion, you must pass a catheter into the new bladder several times a day to drain the urine. This allows you to live without an ostomy bag, but for some patients, passing the catheter several times a day may be difficult or impossible. Third, the new bladder can be directly reattached to the urethra (called an orthotopic neobladder).

Information from other sources on Actos Lawsuit

Bladder cancer is a malignant overgrowth of the cells of the bladder. Most commonly, the growth occurs in cells that are in the urothelium. The lining of most hollow spaces in the body is made of epithelial cells. The lining of the inside of your cheek, for instance, is an epithelial cell lining. Also, the lining of your stomach, bowels, gallbladder, and—you guessed it—the bladder is made of epithelial cells. Each organ has its own subset of epithelial cells. In the bladder, the lining cells are called transitional epithelial cells. The cancer that grows from these cells is then called transitional cell cancer; 90% to 95% of all bladder cancers are of this type. If the cancer grows from a different type of cell in the bladder, it is given a different name. Other types of uncommon cancers in the bladder include squamous cell carcinoma and adenocarcinoma.

It is also possible that cancer in the bladder did not begin there but spread to the bladder from somewhere else. The bladder is an uncommon place for other tumors to “seed” (or metastasize), but it does occasionally occur. Although metastases are uncommon, tumors can occa­sionally grow directly into the bladder from an adjacent organ, such as the prostate, colon, rectum, or cervix. Bladder cancer is the fourth most common type of cancer in men and the eighth most common in women. The American Cancer Society estimated that in 2009, there would be about 70,980 new cases of bladder cancer diagnosed in the United States. In 2009, 14,330 deaths were expected from bladder cancer. In spite of the increased incidence of bladder cancer over the years, the rate of people dying from bladder cancer has decreased over the past 20 years.

Our use of the term or terms Actos Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Lawsuit visit our site often.

Actos Lawsuit

Posted in Alex Begum | Tagged | Leave a comment

Actos Attorneys Resource

By admin | Published January 25, 2012

Actos Attorneys: When an individual has diffuse, high grade cancer of the bladder, even when superficial, bladder removal may be warranted. Many may have widespread carcinoma in situ (CIS) in conjunction with papillary disease. One can expect a high rate of recurrence and a high rate of progression to invasive disease. Generally, intravesical therapy is tried first. If this therapy is unsuccessful, repeated therapy or alternate intravesical therapies can be tried. However, with failure of intravesical therapy, further trials may prove to be equally ineffective and lead to unnecessary delay for potentially definitive curative therapy. Many recommend removal of the bladder if two courses of six weeks of BCG are ineffective. Therefore, radical cystectomy is a treatment option for any individual who is thought to be at significant risk for progression to musclc invasive and potentially metastatic disease.

For individuals with recurrent disease despite tumor removal and intravesical therapy, progression to a more serious, muscle invasive disease is common. The patient at high risk for progression must consider radical cystectomy. If the individual is not a candidate for radical cystectomy because of poor health or the individual refuses cystectomy, radiation therapy can be considered. There are no good studies available and it is difficult to assess the efficacy of radiation alone since it is always combined with TURBT and the completeness of tumor resection is an uncertain variable. In general, radiation plays a minimal role in the treatment of superficial bladder cancer.

For more information on Actos Attorneys follow us on our RSS Feeds.

For those individuals whose bladder tumors are at high risk for recurrence or progression, instillation of agents directly into the bladder can be worthwhile. The forms of therapeutic agents come in two groups: chemotherapy or immunotherapy. It is fortunate the bladder is readily accessible to these agents, allowing for direct action with minimal systemic side effects.

Those individuals at high risk for recurrence and or progression should be considered for this therapy. Individuals with multiple or diffuse superficial tumors, large tumors, high grade tumors, superficially invasive tumors, those with recurrence within one year, or individuals with CIS all should be considered for this treatment. In addition, those with positive cytology after resection or patients with persistent superficial tumors which could not be removed should also be considered.

Information from other sources on Actos Attorneys

The agent is passed via a catheter into the bladder. The passage of the catheter generally takes just a few seconds in a woman, and perhaps ten seconds in a man. The urethral meatus (the outermost part of the urethra) is first cleansed with an antiseptic solution and then the catheter, which is made slippery with a sterile lubricant, is inserted up the urethra and into the bladder. On passage of the catheter, there is minor, short lived discomfort which may be reduced by an injection up the urethra with numbing medication. The various therapeutic agents are not painful during the infusion but may cause side effects afterwards. Depending on the agent instilled, the patient is asked not to void for a period of time afterwards to allow the agent to have its maximal effect on the bladder lining.

BCG is a living but attenuated form of tuberculosis bacteria. Similar to other living vaccines, it is used to create a heightened immunity. There are a number of precautions which must be taken to make sure the BCG is infused safely. BCG should not be infused immediately or shortly after tumor resection. Several weeks should be allowed to pass so the BCG does not gain access into open blood vessels. In addition, BCG should not be infused if the individual has a urinary infection, has active bleeding, or if the catheterization is traumatic and causes bleeding. It should not be used in patients whose immune system is seriously compromised or for those on steroids, which can decrease the immune system.

Our use of the term or terms Actos Attorneys is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Attorneys visit our site often.

Actos Attorneys

Posted in Alex Begum | Tagged | Leave a comment

Actos and Bladder Cancer Process

By admin | Published January 25, 2012

Actos and Bladder Cancer : This is what is usually called a “false-positive” test result. The test was positive in a case where it seems that it should have been negative. Any medical test has a cer­tain false-positive rate (usually very low). The problem with a false-positive result with urine cytology is that there is no way to guarantee the absence of cancer. It is always possible that the cancer is there, but we have not been able to find it yet. Sometimes it can hide in places such as the ureters or kidney where we cannot see as well. Other times, especially with carcinoma in situ, the diseased areas look normal through the cysto- scope but actually harbor serious disease. Because of this, one should never ignore a positive cytology result. Close to 80% of patients with a positive cytology but a negative evaluation will eventually be found to have a urologic malignancy.

For more information on Actos and Bladder Cancer follow us on our RSS Feeds.

The current recommendation for patients with a posi­tive urine cytology and a negative initial evaluation is to repeat the urine cytology 6 to 8 weeks later. Those patients with a negative cytology on the follow-up test do not need further evaluation. If the follow-up cytol­ogy is positive, however, careful evaluation should be undertaken, as most of these patients will eventually be found to have a malignancy. Your urologist may rec­ommend multiple small biopsies of the bladder to look for carcinoma in situ, a condition that is often associ­ated with positive cytology.

Although cytology has long been the gold standard for bladder cancer screening, including monitoring for recur­rences, it is far from perfect (see Question 33), and there is great interest in finding an even better test. Currently, at least four other markers are approved by the Food and Drug Administration (FDA), although none of them are clearly better than cytology. In addition to these four, many new tests are being developed. The four listed here are those that are currently available to patients. If you are considering a radical cystec­tomy, you want an individual who regularly performs that operation. A radical cystectomy is a complicated, time-consuming procedure that some urologists rarely or never perform. The old dictum “practice makes perfect” certainly applies here. Furthermore, if you are interested in the neobladder option for reconstruction of your urinary tract, you should make sure that the urologist is comfortable with that portion of the oper­ation. The neobladder adds complexity to the proce­dure for the surgeon, and not all urologists are well trained in this area. The urologist should know his or her own complication rate for the procedure and not just quote widely published rates for other surgeons. He or she should be comfortable and willing to discuss these rates with you.

Information from other sources on Actos and Bladder Cancer

Cancer can be a frightening word and disease no matter how you look at it. You want a physician who understands your fears and concerns and who is willing to take the time to help you make your management decisions. There is no good measure for this, but trust your instincts at your first meeting with a new doctor. Sometimes you may feel that it is necessary to get a second opinion. You may have concerns about the treatment recommendations or may worry that there are other options that have not been presented. If you ever feel that you have not received enough informa­tion or that you are uncomfortable with the treatment recommendations from your urologist and/or oncolo­gist, then it is appropriate to seek a second opinion.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

Actos and Bladder Cancer

Posted in Alex Begum | Tagged | Leave a comment